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I. Introduction
 The human genome contains approximately 
23,000 protein-coding genes.1  Approximately twenty 
percent of these human genes are patented, with 
some genes being patented as many as twenty times.2 
On May 12, 2009, the Association for Molecular 
Pathology (“AMP”) and nineteen other plaintiffs, 
including healthcare associations and individual doctors, 
researchers, and patients, filed a lawsuit against the United 
States Patent Office (“USPTO”), Myriad Genetics 
(“Myriad”) and ten other individual defendants in their 
capacity as Directors of the University of Utah Research 
Foundation challenging the validity of Myriad’s gene 
patents.3  Myriad holds, through either assignment or 
exclusive license, a number of domestic and international 
patents covering isolated DNA molecules encoding 
the BRCA1 and BRCA2 (“BRCA1/2”) mutations that 
cause an increased risk for the development of breast 
and ovarian cancer and diagnostic methods using 
these isolated DNA molecules to identify a patient’s 
predisposition to the development of familial breast 
cancer.4  In its complaint, AMP alleged that the patent 
claims were invalid under Article 1, Section 8, clause 8 
of the United States Constitution and 35 U.S.C. § 101 
“[b]ecause human genes are products of nature, laws of 
nature and/or natural phenomena, and abstract ideas or 
basic human knowledge or thought.”5  Similarly, AMP 
further asserted that the claims were unconstitutional 
under the First and Fourteenth Amendments to the 
United States Constitution, as they represent patents 
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1.  International Human Genome Sequencing Consortium, 
Finishing the Euchromatic Sequence of the Human Genome, 431 
Nature 931, 942 (2004).
2.  Kyle Jensen and Fiona Murray, Intellectual Property 
Landscape of the Human Genome, 310 Sci. 239, (2005).
3.  Complaint at ¶ 27-29, Ass’n for Molecular Pathology v. 
U.S. Patent & Trademark Office, 702 F.Supp.2d 181 (S.D.N.Y. 
May 12, 2009) (No. 09CV04515), 2009 WL 1343027  [hereinafter 
AMP Complaint].
4.  Id. at ¶ 31.  The challenged patents include US 5,747, 282; 
US 5,837,492; US 5,693,473; US 5,709,999; US 5,710,001; US 
5,753,441; and US 6,033,857.
5.  Id. at ¶ 102.
on abstract ideas or basic human knowledge and/or 
thought.6
 On March 29, 2010, Judge Robert Sweet of the 
United States District Court for the Southern District 
of New York granted the plaintiffs’ motion for summary 
judgment, holding the patents related to BRCA1/2 
invalid.7  Judge Sweet’s resolution of the motion was 
“based upon long recognized principles of molecular 
biology and genetics:  DNA represents the physical 
embodiment of biological information, distinct in its 
essential characteristics from any other chemical found 
in nature.”8  Therefore, Judge Sweet concluded that the 
isolated DNA containing sequences found in nature was 
unpatentable subject matter under 35 U.S.C. § 101.9 
He further concluded that the claimed comparisons 
of DNA involved in the diagnostic methods were 
simply abstract mental processes, also rendering them 
unpatentable under 35 U.S.C. § 101.10  Though 
providing no comfort for Myriad, Judge Sweet granted 
the USPTO’s motion for summary judgment dismissing 
the constitutional claims, invoking the doctrine of 
constitutional avoidance.11  Not surprisingly, Myriad 
filed a Notice of Appeal to the Court of Appeals for the 
Federal Circuit on June 16, 2010.12  Oral arguments 
were heard on April 4, 2011.13
 Although the district court’s decision’s 
applicability is limited to the patents in the instant case, 
if upheld by the Federal Circuit, the decision would 
have far-reaching implications for human gene patents 
currently in force and the future of the biotechnology 
industry, both domestically and abroad.  Therefore, 
this paper seeks to address the legal and policy issues 
6.  Id. at ¶ 103.
7.  Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 702 F. Supp. 2d 181, 232, 237 (S.D.N.Y. Mar. 29, 2010).
8.  Id. at 185.
9.  Id.
10.  Id.
11.  Id. at 237-38.
12.  Notice of Appeal to the Federal Circuit, Association 
for Molecular Pathology v. U.S. Patent & Trademark Office, 702 
F.Supp.2d 181 (S.D.N.Y. June 16, 2010), No. 09 Civ. 4515 (Fed. 
Cir. June 1, 2010).
13.  U.S. Court of Appeals for the Federal Circuit, Oral 
Argument Recordings, http://www.cafc.uscourts.gov/oral-argument-
recordings/search/audio.html. 
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concerning human gene patents in view of the current 
decision in Association for Molecular Pathology v. United 
States Patent & Trademark Office (hereinafter “Myriad”) 
with a view to related cases involving Myriad’s patenting 
of isolated DNA molecules encoding BRCA1/2 in the 
United States and European forums.
II. Background
A.  DNA and Genes – The Information That Life 
Depends On
 Watson and Crick revolutionized genetic 
research in 1953 with their determination of the structure 
of deoxyribonucleic acid (“DNA”) and the elucidation of 
the implications for such a structure in genetic research.14 
DNA exists in nature as linear sequences of nucleotides 
(chemical units known as adenine, thymine, guanine, 
and cytosine) that are packaged into chromosomes.  Each 
chromosome contains hundreds of genes, occurring one 
after the other as discrete lengths of sequence within 
the linear DNA.  The order of the nucleotide sequences 
within a gene determines the functioning of that gene, 
and the characteristics of individual genes collectively 
contribute to the genetic traits a person receives.  
 How does the nucleotide sequence determine 
the functioning of a gene?  Crick articulated this process 
within the framework of what is known as the central 
dogma of molecular biology.15  The central dogma 
outlines the process by which genes are expressed; in 
other words, it describes the mechanism by which the 
genetic instructions contained in the nucleotide sequence 
of a gene effectuate a function within a cell.  Essentially, 
DNA is copied repeatedly into a similar form known 
as mRNA (transcription), and these numerous copies 
of mRNA are turned into protein (translation).  These 
proteins then interact to carry out a host of functions 
within the cell.  A simple analogy illustrates the concept: 
A person reads instructions (“DNA”) for how to put 
a table together, and that person’s brain processes the 
information (“transcription”) into a signal (“mRNA”); 
that person’s brain then sends out that signal (“mRNA”) 
telling their body to carry out the processed instructions 
from the brain to put the table (“proteins”) together 
14.  See Miri Yoon, Gene Patenting Debate:  The Meaning of 
Myriad, 9 J. Marshall Rev. Int. Prop. L. 953, 954 (2010); see 
also James. D. Watson & Francis H. Crick, Molecular Structure 
of Nucleic Acid:  A Structure for Deoxyribose Nucleic Acid, 171 
Nature 737 (1953); James D. Watson & Francis H. Crick, Genetic 
Implications of the Structure of Deoxyribonucleic Acid, 171 Nature 
964 (1953).
15.  See Francis Crick, On Protein Synthesis, Symp. Soc. Exp. 
Biol. XII 139 (1958) (presenting a new theory of how genes affect 
protein expression and function).
(“translation”).
 Importantly, alterations in the nucleotide 
sequences, called mutations, can occur, principally by 
either faulty repair of DNA damage or imperfect copying 
of DNA when it is passed on to new cells.  Many of 
these mutations are silent, resulting in no perceptible 
consequences.  However, certain specific mutations can 
increase a person’s risk for the development of a variety of 
serious diseases, including cancer.16  Accordingly, certain 
mutations of the “breast cancer 1, early onset” and 
“breast cancer 2, early onset” (BRCA1/2) genes lead to 
increased risk of breast and ovarian cancer.  The average 
woman in the United States, without such a mutation, 
has about a 12% chance of developing breast cancer 
in her lifetime, but carriage of an abnormal BRCA1 or 
BRCA2 gene augments this to about an 80% chance.17 
With regard to ovarian cancer, the average woman has 
an approximately 1.4% chance of developing ovarian 
cancer, but for a woman with a BRCA1 or BRCA2 
mutation that risk increases to 15% to 40%.18
 Because an increased risk for breast or ovarian 
cancer has many implications for an individual’s choice 
of lifestyle and preventative care, the scientific and 
healthcare communities have begun to intensify research 
into genetic testing to facilitate early identification 
of BRCA1/2 mutations in patients.  Genetic testing 
for mutations within an individual’s DNA sequence 
is carried out by one of a number of methodologies 
collectively known as gene sequencing, which allows 
determinations of the exact order of nucleotides within 
a strand of linear DNA.19  Essentially, fluorescent tags 
of four distinct colors corresponding to each of the four 
nucleotides (adenine, guanine, cytosine, and thymine) 
16.  See Marisa Noelle Pins, Impeding Access to Quality Patient 
Care and Patient Rights:  How Myriad Genetics’ Gene Patents Are 
Unknowingly Killing Cancer Patients and How to Calm the Ripple 
Effect, 17 J. Intell. Prop. L. 377, 384 (2010) (noting that some 
inherited mutations may increase a “person’s risk for a variety of 
diseases, while others are innocuous”).
17.  Cancer Risk and Abnormal Breast Cancer Genes, 
Breastcancer.org, http://www.breastcancer.org/risk/genetic/
bcrisk_abnrml_genes.jsp (last visited Oct. 22, 2010).  It is 
important to note that hundreds of potential mutations have been 
identified in BRCA1/2 genes, each one carrying with it a different 
level of risk of the development of breast and ovarian cancer.  
These percentages simply quantify overall risk for according to the 
frequency of each distinct mutation in the female population of the 
United States.
18.  BRCA1 and BRCA2:  Cancer Risk and Genetic Testing, 
National Cancer Institute, http://www.cancer.gov/cancertopics/
factsheet/risk/brca#r4 (last visited March 7, 2010).
19.  A Brief Guide to Genomics, Nat’l Human Genome 
Research Inst., http://www.genome.gov/18016863 (last visited 
Oct. 22, 2010).
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are allowed to bind to the DNA.20  These fluorescent 
tags are identified by a detector, which provides the 
information to a computer in order to reconstruct the 
entire gene sequence.21 
 In order to perform gene sequencing, the 
specific gene to be sequenced is purified and isolated 
from the individual’s body prior to the introduction 
of the fluorescent tags.22  The term “purified” implies 
isolation from the gene’s natural state,23 whereas the term 
“isolation” implies removal from the body and separation 
from the surrounding cellular material.24  This purified 
and isolated DNA molecule that encodes such a gene 
may therefore be the same in sequence as the naturally 
occurring gene, albeit with an altered chemical structure 
due to the removal of associated cellular products that 
facilitate packaging of the DNA into a chromosome. 
Under the current USPTO policy, such a purified and 
isolated DNA molecule is patent eligible.25
B. Patenting of Genes and Other Biological 
Materials in the United States
1. Development of United States Case Law
 The United States Constitution gives Congress 
the power “[t]o promote the Progress of Science and 
useful Arts, by securing for limited Times to…Inventors 
the exclusive Right to their respective…Discoveries.”26 
Under this authority, Congress enacted the first Patent 
Act in 179027 and the most recently revised Act in 1952.28 
35 U.S.C. §101 describes patentable subject matter as 
“any new and useful process, machine, manufacture 
or composition of matter.”29  Famously, in Diamond v. 
20.  Id.
21.  Id.
22.  Pins, supra note 16.
23.  See Pins supra note 16 (citing United States Patent & 
Trademark Office, Utility Examination Guidelines, 66 Fed. Reg. 
1092, 1093 (Jan. 5, 2001)).
24.  See id. (citing Plaintiff’s Memorandum of Law in Support 
of Motion for Summary Judgment at 2, Ass’n for Molecular 
Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 
2009 WL 3269113 (S.D.N.Y. Aug. 26, 2009).
25.  See USPTO, Utility Examination Guidelines, 66 
Fed. Reg. 1092, 1093 (Jan. 5, 2001) [hereinafter Examination 
Guidelines] (stating that “an inventor’s discovery of a gene can be 
the basis for a patent on the genetic composition isolated from its 
natural state and processed through purifying steps that separate the 
gene from other molecules naturally associated with it.”).
26.  U.S. Const. art. I, § 8, cl. 8.
27.  An Act to Promote the Progress of Useful Arts, 1 Stat. 109 
(1790).
28.  Act of 1952, 66 Stat. 792 (1952) (codified as amended at 
35 U.S.C. § 101).
29.  35 U.S.C. § 101 (codification of the amended Patent Act 
of 1952).
Chakrabarty, the Supreme Court broadly construed such 
statutory subject matter “to include anything under the 
sun that is made by man,”30 but went on to hold that 
“laws of nature, physical phenomena, and abstract ideas” 
are excluded from patent-eligible subject matter.31
 Under early cases, purified natural products 
were generally held to be unpatentable.  It is important 
to note that despite its conclusions of patent-ineligibility, 
the Supreme Court did not appear to rely on the fact that 
the subject matter was a product of nature,32 but rather a 
lack of novelty33 evidenced by an inability to distinguish 
between the natural and purified/synthetic compositions. 
In American Wood-Paper Co. v. Fibre Disintegrating Co., 
the court invalidated a patent for extracted wood pulp 
because it found the purified product to be the same as 
the natural product.34  Similarly, in Cochrane v. Badische 
Anilin & Soda Fabrik,35 the court held that a synthetic 
dye was not a new composition because it had the same 
chemical makeup as the natural dye.36  
 However, this line of reasoning was challenged 
in a line of cases holding that isolation and purification 
may alter a composition of matter so as to render it 
patent-eligible.  Within the chemical context, the court 
in Union Carbide Co. v. American Carbide Co.37 found 
that a crystalline product described in the application was 
different from an amorphous product found in the prior 
art due to physical properties that made it better suited 
for commercial use in gas generators.38  Similarly, in 
Kuehmsted v. Farbenfabriken of Elberfeld Co.,39 the court 
upheld a patent for a form of aspirin (acetyl salicylic acid) 
purified by a process resulting in an increased therapeutic 
effect compared to aspirin purified by previous methods.40 
The court noted that “though the difference . . . be one 
30.  Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) 
(quoting S. Rep. No. 1979, 82d Cong., 2d Sess., 5 (1952) and H.R. 
Rep. No. 1923, 82d Cong., 2d. Sess., 6 (1952)).
31.  Id. at 309 (citing Parker v. Flook, 437 U.S. 584 
(1978);Gottschalk v. Benson, 409 U.S. 63, 67, (1972); Funk Brothers 
Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130, (1948); O’Reilly 
v. Morse, 56 U.S. 62, 112-121, (1854); Le Roy v. Tatham, 55 U.S. 
156, 175  (1853)). 
32.  See Yoon, supra note 14 at 962.
33.  The use of the term “novelty” here refers to the inclusion 
of the term “new” in the 35 U.S.C. § 101 of patentable subject 
matter as contrasted with the statutory bar relating to novelty set 
out in 35 U.S.C. § 102.
34.  American Wood-Paper Co. v. Fibre Disintegrating Co., 90 
U.S. 566, 596 (1874);  Pins, supra note 16 at 388.
35.  111 U.S. 293 (1884).
36.  Id. at 311.; see also Pins, supra note 16, at 388.
37.  181 F. 104 (2d Cir. 1910).
38.  Id. at 107.
39.  179 F. 701 (7th Cir. 1910).
40.  Id. at 705.
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of purification only—strictly marking the line, however, 
where the one is therapeutically available and the others 
were therapeutically unavailable—patentability would 
follow.”41  This logic formed the basis for one of the most 
notable cases examining the patentability of biological 
materials, Parke-Davis & Co. v. H. K. Mulford Co.42  In 
that decision, Judge Learned Hand held that a patent 
for adrenaline was valid because the adrenaline had 
been isolated from nature.43  Specifically, the inventor 
had made it available for any use by removing it from 
other gland tissue in which it was found, thereby 
transforming it for every practical purpose into a new 
thing, commercially and therapeutically.44  
 Such decisions paved the way for the 
patentability of biological products in their isolated 
and purified form, a view that garnered further support 
from the Court of Customs and Patent Appeals in 
Application of Bergstrom.45  In that case, the court held 
that two chemical entities of the prostaglandin family 
extracted from prostate glands were patentable because 
the compounds were not naturally occurring in their 
purified form.46  The court asserted that pure materials 
differ from impure materials by definition,47 and if 
impure materials are the only ones existing and available, 
consequently, the pure materials are new with respect to 
the impure materials.48  
 Accordingly, courts have implicitly recognized 
the patent-eligibility of purified and isolated DNA 
molecules.  In Amgen, Inc. v. Chugai Pharmaceuticals 
Co.,49 the district court accepted the defendant’s assertion 
that the claimed invention was a purified and isolated 
DNA sequence encoding human erythropoietin, i.e. 
the cloned gene rather than the sequence listing per se.50 
Therefore, the claim was not directed towards a sequence 
that would be “a nonpatentable natural phenomenon 
‘free to all men and reserved exclusively to none.’”51  The 
41.  Id.
42.  189 F. 95 (C.C.S.D.N.Y. 1911).
43.  Id. at 103.
44.  Id.
45.  427 F.2d 1394 (C.C.P.A. 1970).
46.  Id. at 1401-02.
47.  Id. at 1401 n. 10 (“Webster’s . . . defines ‘pure’ as ‘Separate 
from all heterogeneous or extraneous matter; free from mixture 
or combination. . . .”) (quoting Webster’s New International 
Dictionary, (2d ed. 1954)).
48.  Id. at 1402.
49.  No. 87-2617-Y, 1989 WL 169006, 13 U.S.P.Q.2d 1737 
(D. Mass. Dec. 11, 1989) aff’d in part, vacated in part, 927 F.2d 
1200, 1219 (Fed. Cir. 1991).
50.  Id. at *32, 13 U.S.P.Q.2d at 1759.
51.  Id. (quoting Diamond v. Chakrabarty, 447 U.S. 303, 309 
(1980)).
Federal Circuit accepted the district court’s construction 
of the claim, specifying the subject matter as “the novel 
purified and isolated sequence which codes for EPO.”52
 Though the Supreme Court has not directly 
addressed the issue of purified and isolated gene 
sequences in the context of patent eligibility, an 
affirmative decision would be in accord with its previous 
decisions.  With regard to biological products, the 
Court in Diamond held that a bacterium genetically 
engineered to carry multiple oil-degrading plasmids fell 
within the ambit of patentable subject matter.53  The 
Court concluded that the claimed microorganism was 
a “nonnaturally occurring manufacture or composition 
of matter” having “markedly different characteristics 
from any found in nature,” contrasting it with “a new 
mineral discovered in the earth or a new plant found 
in the wild.”54  This holding has been interpreted by 
at least one commentator to mean that natural things 
left unaltered by human intervention are unpatentable 
products of nature, while some natural things may be 
so transformed by man that they cease to be products 
of nature.55  Thus, the crucial question before the Court 
in the instant appeal will be whether purification and 
isolation of a genetic sequence results in a nonnaturally 
occurring composition of matter with characteristics 
markedly different from those of DNA in its natural 
state sufficient to render it patentable subject matter.
2. Current Position of the USPTO
 The USPTO has granted 4270 patents 
containing claims directed to about 4382 human genes.56 
In promulgating its Utility Examination Guidelines, the 
USPTO responded to a number of comments received 
regarding the patent-eligibility of human genes.57 
Many such comments opined that a gene is not a new 
composition of matter because it exists in nature, and 
consequently, an inventor who isolates a gene does not 
actually invent or discover a patentable composition.58 
52.  Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 
1206 (Fed. Cir. 1991) (placing emphasis upon the terms “purified 
and isolated”), see also In re Kubin, 561 F.3d 1351, 1352 (Fed. 
Cir. 2009) (noting that “[t]his case presents a claim to a classic 
biotechnology invention—the isolation and sequencing of a human 
gene that encodes a particular domain of a protein”).
53.  Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
54.  Id. at 309-10.
55.  Richard S. Gipstein, Note, The Isolation and Purification 
Exception to the General Unpatentability of Products of Nature, 4 
Colum. Sci. & Tech. L. Rev. 1, 3-4 (2003).
56.  Jensen & Murray, supra note 2, at 239.
57.  See Utility Examination Guidelines, 66 Fed. Reg. 
1092, 1092 (Jan. 5, 2001) . 
58.  Id. at 1093.
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In response, the USPTO asserted that “a patent claim 
directed to an isolated and purified DNA molecule 
could cover a gene excised from a natural chromosome 
or a synthesized DNA molecule.”59  Relying on Parke-
Davis and In re Bergstrom, the USPTO emphasized 
that a molecule having the same sequence as a naturally 
occurring gene is patent-eligible because (1) an excised 
gene is patent-eligible as a composition of matter because 
that DNA molecule does not occur in that isolated form 
in nature or (2) a synthetic DNA preparation is patent-
eligible because its purified state is different from the 
naturally occurring compound.60
3. The District Court’s Decision in Myriad
 Myriad holds, through assignment or exclusive 
license, several U.S. patents on the isolated DNA 
molecules relating to the BRCA1/2 sequences.61  Myriad 
did not enforce its patents against academic research 
institutions,62 but regularly sought enforcement against 
both research institutions and commercial entities 
providing commercial diagnostic testing through cease-
and-desist letters63 and litigation.64  At least nine clinical 
diagnostic laboratories ceased BRCA1/2 testing due 
to Myriad’s patent holdings.65  Myriad’s enforcement 
actions precipitated AMP’s request for declaratory 
judgment that Myriad’s patents on human BRCA1/2 are 
invalid under 35 U.S.C. § 101 and are unconstitutional 
because the granting of human gene patents by the 
USPTO violates Article I, section 8, clause 8 and the 
First Amendment of the Constitution.66  
 The claims addressed by the lawsuit fall into 
two main categories: composition claims and method 
(process) claims.67  The composition claims are directed 
to isolated and purified DNA molecules that encode 
either normal (wild-type) or mutant forms of BRCA1/2 
59.  Id. (emphasis added).
60.  Id.
61.  AMP Complaint, supra note 3, at ¶ 31.
62.  Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 669 F. Supp. 2d. 365, 379 (S.D.N.Y. 2009) (referencing 
letter to National Cancer Institute investigator assuring her that 
Myriad would not interfere with her research activities).
63.  See id. at 378–379 (discussing letters sent to the 
University of Pennsylvania, Georgetown, and Yale).
64.  See id (discussing the litigation it was involved in with 
Oncormed and the University of Pennsylvania).
65.  Id. at 380; Mildred K. Cho, et al., Effects of Patents and 
License on the Provision of Genetic Testing Services, 5 J. Molecular 
Diagnostics 3, Table 2 (2003).
66.  AMP Complaint, supra note 3., at ¶ 102.
67.  See Ass’n for Molecular Pathology v. U.S. Patent & 
Trademark Office, 702 F. Supp. 2d 181, 212 (S.D.N.Y. 2010).
proteins.68  A representative composition claim is claim 
one of U.S. Patent 5,747,282, which reads, “[a]n isolated 
DNA coding for a BRCA1 polypeptide, said polypeptide 
having the [following] amino acid sequence.”69  The 
method claims are directed to diagnostic methods for 
assessing a patient’s predisposition to the development 
of breast and ovarian cancer using such isolated DNA 
molecules as identified in the composition claims.  A 
representative method claim is claim twenty of U.S. 
Patent 5,753,441, which reads:
A method for detecting a germline 
alteration in a BRCA1 gene, said 
alteration selected from the group 
consisting of the alterations set forth 
in [the Tables] . . . which comprise[] 
analyzing a sequence of the BRCA1 
gene or BRCA1 RNA from a human 
sample or analyzing the sequence 
of BRCA1 CDNA [sic] made from 
mRNA from said sample.70
 Several pre-trial motions were submitted to the 
court:  1) AMP moved for summary judgment, declaring 
that Myriad’s patents were invalid;71 2) Myriad moved 
for summary judgment to dismiss AMP’s complaint for 
lack of subject-matter jurisdiction, characterizing the 
suit as consisting of a mere policy disagreement rather 
than a real controversy;72 and 3) the USPTO moved 
for judgment on the pleadings under the doctrine of 
constitutional avoidance.73  The court stayed AMP’s 
68.  Id. at 211-12.
69.  U.S. Patent No. 5,747,282 col. 153 ll. 56–59 (filed June 
7, 1995).
70.  U.S. Patent No. 5,753,441 col. 157 ll. 11-17 (filed Jan. 5, 
1996).  Method claims will not be discussed in detail as these claims 
are beyond the scope of this paper.
71.  Plaintiff’s Memorandum of Law in Support of Motion 
for Summary Judgment, Ass’n for Molecular Pathology v. U.S. 
Patent & Trademark Office, No. 09 Civ. 4515, 2009 WL 3269113 
(S.D.N.Y. Aug. 26, 2009).
72.  Memorandum of Law in Support of Defendant’s Motion 
to Dismiss, Ass’n for Molecular Pathology v. U.S. Patent & 
Trademark Office, 2009 WL 3269109 (S.D.N.Y. July 13, 2009) 
(”This case is clearly a thinly veiled attempt to challenge the 
validity of patents where, other than an overall policy disagreement 
concerning the legitimacy of gene patents, the plaintiffs have no 
actual dispute with the Defendants over patent infringement.”).
73.  Memorandum of Law in Support of Defendant United 
States Patent & Trademark Office’s Motion for Judgment on the 
Pleadings and in Opposition to Plaintiff’s Motion for Summary 
Judgment, Ass’n for Molecular Pathology v. U.S. Patent & 
Trademark Office, 2009 WL 5785024 (S.D.N.Y. Dec. 24, 2009) 
(“Because plaintiffs have not identified any way in which the 
Constitution imposes limits on patents beyond those already 
imposed by the patent laws, plaintiffs’ First Amendment claim 
merges with their statutory claims, and should therefore be 
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Motion for Summary Judgment pending its resolution 
of Myriad’s motion to dismiss.74  On November 2, 2009, 
the court denied Myriad’s motion to dismiss, stating that 
“[t]he novel circumstances presented by this action . . ., 
the absence of any remedy provided in the Patent Act, 
and the important constitutional rights the Plaintiffs 
seek to vindicate establish subject matter jurisdiction 
over the Plaintiffs’ claim.”75  Ultimately, the USPTO’s 
motion for judgment on the pleadings was granted, 
dismissing the plaintiffs’ claims.76  Most significantly, 
on March 29, 2010, the court granted AMP’s motion 
for summary judgment, resulting in invalidation of the 
challenged patent claims relating to Myriad’s BRCA1/2 
composition and method claims.77
 Though the Supreme Court has never made a 
general statement that products of nature are patent-
ineligible,78 the district court concluded that exclusion 
of products of nature under 35 U.S.C. § 101 “reflects 
the Supreme Court’s recognition that ‘phenomena 
of nature . . . are not patentable.’”79  Thus, the court 
delineated its sole task as determining “whether the 
claimed invention . . . falls within the judicially created 
‘products of nature’ exception.”80  Consistent with several 
of the cases cited supra,81 the court acknowledged that a 
change in a product of nature resulting in the creation 
of a fundamentally new product would be eligible for 
a patent.82  Using the restrictive language of Diamond 
requiring that the product possess “markedly different 
characteristics” to establish creation of a fundamentally 
new product,83 the court concluded that isolated and 
purified DNA does not possess markedly different 
characteristics from native DNA.84
C. Patenting of Genes in Europe
1. European Patent Convention
dismissed.”).
74.  Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 669 F. Supp. 2d. 365, 374 (S.D.N.Y. 2009).
75.  Id. at 383.
76.  Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 702 F. Supp. 2d 181, 238 (S.D.N.Y. 2010).
77.  Id. at 232, 237.
78.  Yoon, supra note 14, at 962 (citing Am. Fruit Growers, 
Inc. v. Brodgex Co., 283 U.S. 1,11 (1931); Am. Wood-Paper Co v. 
Fibre Disintegrating Co., 90 U.S. 566, 577-596 (1874); Cochrane 
v. Badische Anilin & Soda Fabrik, 111 U.S. 293, 311 (1884)..
79.  Ass’n for Molecular Pathology, 702 F. Supp. 2d at 218-19 
(citing Gottschalk v. Benson, 409 U.S. 63, 67 (1972)).
80.  Id. at 220.
81.  See cases cited supra notes 36, 38, 43, 46, 50, 54.
82.  Ass’n for Molecular Pathology, 702 F. Supp. 2d at 222.
83.  Id. at 229 (citing Chakrabarty, 447 U.S. at 310 (1980)).
84.  Id. at 232.
 The European Patent Convention (“EPC”) 
is a multilateral treaty that instituted the European 
Patent Organization in order to provide an autonomous 
legal system by which European patents are granted. 
Practically, the grant of a European patent does 
not provide a unitary right, but rather a “group” of 
essentially independent patents granted on a single 
application, nationally-enforceable and nationally-
revocable by Contracting states.85  The EPC provides a 
legal framework for the granting of European patents 
through a single, harmonized procedure before the 
European Patent Office (“EPO”), a division of the 
European Patent Organization.86  
 The EPC requires that patents be granted for 
“any inventions which are susceptible of industrial 
application.”87  Exceptions covering inventions 
considered “discoveries, scientific theories, and 
mathematical methods,” among others, are codified 
within the treaty,88 rather than derived from case law 
as in the United States.  In addition, the European 
Union may issue directives interpreting treaties such 
as the EPC that require compliance by member States 
through harmonization of their national laws to make 
them consistent with the directive.89  Notably, the 
European Union Biotech Directive interpreted the EPC 
patentable subject matter exceptions narrowly, affirming 
that isolated biological material is considered patentable 
subject matter even if previously occurring in nature.90 
The Directive further specifies that, if isolated from the 
human body, “the sequence or partial sequence of a 
gene” may constitute patentable subject matter, so long 
as the industrial application of that sequence is disclosed 
85.  Convention on the Grant of European Patents, art. 
2(2), Oct. 5, 1973, 1065 U.N.T.S. 199 [hereinafter European 
Patent Convention]; see also Case C-539/03, Roche Nederland 
BV v. Frederick Primus, 2006 E.C.R. I-06535; Case C-4/03, 
Gesellschaft für Antriebstechnik mbH & Co. KG v. Lamellen und 
Kupplungsbau Beteiligungs KG, 2006 E.C.R. I-06509.
86.  European Patent Convention, supra note 86, at art. 2(1).
87.  Id. at art. 52 (emphasis added).  Note the similarity in 
breadth to the language of 35 U.S.C. § 101 requiring “any new and 
useful process, machine, manufacture or composition of matter” for 
patentability. (emphasis added)
88.  Id. at art. 52(2).  Other less germane exceptions include 
aesthetic creations, schemes, rules and methods for performing 
mental acts, playing games or doing business, programs for 
computers, and presentations of information. 
89.  John Conley, European Court Issues a Gene Patent Ruling 
Against Monsanto—A Myriad Connection?, Genomics Law Report 
(July 28, 2010), http://www.genomicslawreport.com/index.
php/2010/07/28/european-court-issues-gene-patent-ruling-against-
monsanto-a-myriad-connection/.
90.  Council Directive 98/44, art. 3, 1998 O.J. (L 213) 13-21 
(EC).
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in the patent application.91  
 A European patent is subject to revocation 
or narrowing by the EPO by either of two types of 
post-grant procedure—an opposition procedure or a 
limitation and revocation procedure.92  The opposition 
procedure may initiated by any interested person from 
the public who believes that the patent should not have 
been granted.93  The opposition must be based on the 
grounds set forth in Article 100 of the EPC,94 which 
include that the invention lacks novelty, an inventive 
step, or industrial application, and be received within 
nine months of publication that the patent has been 
granted.95  Once an opposition is filed, the opposition 
division, consisting of three experienced examiners, 
begins an investigation that includes examination of the 
patent, invitation to the parties to file any observations, 
and, typically, oral proceedings.96  The final outcome is 
one of three possibilities:  (1) revocation of the patent, 
(2) maintenance of the patent, or (3) maintenance of the 
patent in amended form.97  Subsequent to the decision 
of the opposition division, the parties have the option to 
appeal to the independent boards of appeal.98
2. European Patent Office’s Treatment of 
Myriad’s Patents
 The EPO granted four patents to Myriad 
covering the BRCA1/2 genes and related diagnostic 
methods,99 one of which claimed the isolated DNA 
molecule encoding BRCA1.100  Opposition to the ‘902 
patent was filed on August 28, 2002 by organizations 
from eleven European countries101 on multiple grounds 
91.  Id. at art. 5.
92.  European Patent Office, The Opposition Procedure, 
http://www.epo.org/about-us/jobs/examiner/role/opposition.html 
(last visited November 12, 2010).
93.  Id.; see also Pins, supra note 16, at 401.
94.  European Patent Convention, supra note 86, at art. 100.
95.  The Opposition Procedure, supra note 94; See also 
European Patent Convention, supra note 86, at art. 100(a).
96.  The Opposition Procedure, supra note 94.  Prior to the 




99.  EPO 0699754 (issued Jan. 10, 2001); EPO 0705902 
(issued Nov. 28, 2001); EPO 0705903 (issued May 23, 2001); EPO 
0785216 (issued Jan. 8, 2003).
100.  EPO 0705902 (entitled 17q-linked breast and ovarian 
cancer susceptibility gene)
101.  Jordan Paradise, European Opposition to Exclusive Control 
Over Predictive Breast Cancer Testing and the Inherent Implications 
for U.S. Patent Law and Public Policy:  A Case Study of the Myriad 
Genetics’BRCA Patent Controversy, 59 Food & Drug L.J. 133, 138 
(2004) [Hereinafter Opposition].  The eleven countries are Austria, 
Belgium, Czech Republic, Denmark, Finland, Germany, Greece, 
including lack of novelty, inventive step, and/or industrial 
application.102  As for lack of novelty, Myriad claimed a 
priority date to a patent application filed in the U.S. in 
1994103 in which the BRCA1 sequence listing contained 
ten errors ultimately requiring amendment on March 24, 
1995 to reflect the correct sequence.104  During that time, 
the molecule encoding BRCA1 was isolated by other 
researchers and its sequence placed in scientific databases 
and numerous articles in the public domain.105  Thus, 
the challengers contended that the incorrect sequence in 
the 1994 application could not overcome the absolute 
novelty bar of the European patent system.106  With 
regard to lack of inventive step, previous work of the 
Breast Cancer Linkage Consortium had narrowed down 
the region of the chromosome containing the BRCA1 
gene considerably, so much so that one researcher felt 
that it was only a matter of luck as to which individual 
researcher would find it.107  In connection with lack 
of industrial application, the challengers focused on 
Article 52(4) of the EPC, which states that “diagnostic 
methods practiced on the human . . . body shall not be 
regarded as inventions which are susceptible of industrial 
application.”108  Though the claim was directed towards 
the isolated DNA molecule, the only use of that molecule 
supported by the specification fell within the context of 
a diagnostic method.
 The opposition division failed to reach any 
conclusions regarding the assertions of the challengers 
regarding patentable subject matter, but instead 
determined that Myriad improperly extended the 
subject matter by amendment of claims after issuance 
of the patent in violation of Article 123(2).109  As a 
result, the patent was severely limited by invalidation of 
claims directed towards the isolated BRCA1 molecule; 
diagnostic methods; BRCA1 protein; conceivable 
Italy, the Netherlands, Switzerland, and the United Kingdom.
102.  Id.
103.  Id. at 142.
104.  Maurice Cassier, The Opposition Against the Patent of 
Myriad Genetics and Their Total or Partial Revocation in Europe:  
Early Conclusions, 21(6) Médicine Sciences (2005), available at 
http://www.edk.fr/reserve/revues/ms_papier/e-docs/00/00/07/91/
document_article.md (translated by Google).
105.  Opposition, supra note 102, at 142.
106.  Id.
107.  Id. at 143.
108.  European Patent Convention, supra note 86, at Art. 
52(4); Opposition, supra note 102, at 144.
109.  European Patent Convention, supra note 86, at Art. 
123(2); Jordan K. Paradise, Lessons from the European Union:  The 
Need for a Post-Grant Mechanism for Third-Party Challenge to 
U.S. Patents, 7 Minn. J.L. Sci. & Tech. 315, 320-321 (2006) 
[Hereinafter Lessons].
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therapeutic applications in gene therapy, drug screening, 
and transgenic animals; and diagnostic kits.110  After the 
opposition division’s decision, the new patent issued on 
June 8, 2008, with only three claims directed towards 
a BRCA1 DNA probe and a vector coding for said 
probe.111  It appears that the EPO tacitly recognized the 
validity of the challengers’ policy arguments in crafting 
its decision but specifically sought to avoid making any 
conclusions that might call into question the validity of 
European patents on isolated DNA molecules.
3.  Recent Developments in European Case 
Law
 Monsanto Technology LLC v. Cefetra B.V.112 
is the first and only national court referral to the 
European Court of Justice seeking an interpretation of 
the EU Biotech Directive.  Monsanto holds a European 
patent claiming modified soybean DNA molecules that 
confer the plant immunity to certain herbicides, also 
manufactured by Monsanto.113  Cefetra, in an attempt 
to take advantage of Monsanto’s lack of an Argentinean 
patent covering the technology, imported soy meal 
containing “dead” versions of the subject DNA sequences 
into the Netherlands.114  Monsanto sued Cefetra in a 
Dutch court for violation of national patent law, which, 
similarly to that of the U.S., conveys an exclusive right 
on the patent holder to exclude others from importing 
the patented product.115
 Cefetra asserted that the EU Biotech Directive 
supersedes Dutch patent law.  Specifically, Article 9 
provides that protection extends to “all material . . . in 
which the [patented] product is incorporated and in 
which the genetic information is contained and performs 
its function.”116  The Dutch court referred to the European 
Court of Justice the question of whether absolute 
protection of a DNA sequence, as such, is permissible 
under the Directive despite the fact that the sequence 
did not express its function at the time of importation.117 
The European Court of Justice determined that such 
110.  Lessons, supra note 110, at 321.
111.  Eur. Patent No. 0705902 (filed on Aug. 11, 1995).
112.  Case C-428/08, Monsanto Tech., LLC v. Cefetra B.V., 
2010, http://curia.europa.eu/jcms/jcms/j_6/ (write case number 
in “Case no” box; then click “Search”; choose the “2010-07-06 
Judgment”).
113.  Id.; Conley, supra note 90.
114.  Id.
115.  Id.; Rijksoctrooiwet [Law on Patents] art. 53 (Neth).
116.  Council and Parliament Directive 98/44, art. 9, 1998 
O.J. (L 213) (EC) available at http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CELEX:31998L0044:EN:HTML.
117.  Case C-428/08, Monsanto Tech., LLC v. Cefetra B.V., 
2010; Conley, supra note 90.
protection provided by Dutch patent law violated Article 
9 of the Directive.118  The court stated that “a mere DNA 
sequence without indication of a function does not 
contain any technical information and is therefore not a 
patentable invention.119  
 Though the court’s ruling does not preclude 
the patenting of genes, it appears to preclude absolute 
protection of an isolated DNA molecule per se.  Notably, 
the court’s language emphasizing a DNA molecule’s 
performance of function bears an interesting connection 
to that of the district court in Myriad—it is not the 
chemistry of the DNA sequence that is important, but 
rather the function (i.e., information-delivering) of that 
sequence.120  Because this decision was held to apply 
retroactively, it remains to be seen what effect it will have 
on gene patents such as those held by Myriad.  Arguably, 
under a more liberal view, the isolated DNA molecules 
generated in the course of sequencing are not capable 
of performing their function, making those molecules 
ineligible for patent coverage in the European Union in 
the diagnostic context.121
III. Arguments Surrounding the Gene Patenting 
Debate
 Parties on both sides of the gene patenting 
debate have presented a number of valid arguments to 
support their position.  Opponents of gene patenting 
assert that gene patents impede access to genetic testing, 
hinder attempts to increase the quality of genetic testing, 
and create barriers to basic research on certain genetic 
mutations underlying development of disease.  On the 
other hand, proponents argue that isolated and purified 
DNA is patentable subject matter, regardless of the 
policy arguments against gene patenting, and that gene 
patents stimulate investment in development of genetic 
testing and further basic research related to the genetic 
mutations that are the subject of such testing.  In the 
end, because isolated and purified DNA is patentable 
subject matter and patents on genetic testing are crucial 
for obtaining much-needed research dollars, the Court 
of the Appeals for the Federal Circuit should overturn 
the district court’s decision in Myriad.   
118.  Id.
119.  Case C-428/08, Monsanto Tech., LLC v. Cefetra B.V., 
2010 (citing Counsel Directive, supra note 91 at Recital 23).
120.  Conley, supra note 90.
121.  Chris Holman, Monsanto v. Cefetra:  EU Court of 
Justice Limits Scope of Patent Protection Available to Gene Sequences, 
Holman’s Biotech IP Blog, http://holmansbiotechipblog.
blogspot.com/2010/07/monsanto-v-cefetra-eu-court-of-justice.
html, (last visited Nov. 18, 2010).
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A. The Arguments Against Gene Patenting122
1.   Gene Patents Impede Access to Patient 
Testing
 As both the plaintiffs and the Secretary’s 
Advisory Committee on Genetics, Health, and Society 
(“SACGHS”) have recognized, the issue of limited access 
typically arises in the context of a sole service provider.123 
The basis for this argument lies in the assumption that 
patents associated with genetic tests limit access by 
raising prices above what would exist in the competitive 
market.124  As a result many insurance carriers will not 
cover testing, requiring patients to pay for the test out-
of-pocket.125  Though the test remains available to such 
patients for such a premium, many patients, such as 
those covered under state-run Medicaid programs, may 
be forced to forego testing because they cannot afford 
it.126  However, at least one case study demonstrated 
that the per-unit price of the BRCA test is actually 
comparable to a similar colon-cancer test for which the 
patents have been nonexclusively licensed.127  In fact, the 
SACGHS concluded there is no evidence that patents 
have consistently led to higher prices for genetic tests.128 
 Viewing this issue from another perspective, 
lack of patient access results from insurance industry 
practices, rather than from patent exclusivity.  As a 
predictive genetic test, the BRCA test provides only a 
general estimate of patients’ chances of developing breast 
cancer, as it fails to take into account the influence of 
other mutations and environmental factors, meaning 
many women who test positive will never develop 
breast cancer.129  Such technological limitations may 
lead an insurance carrier to allocate its resources to 
forms of testing that provide more concrete information 
to patients.  Indeed, there are a number of diagnostic 
tests currently available that would provide beneficial 
medical information to patients, whether in the context 
122.  See supra Section II(B)(3).
123.  AMP Complaint, supra note 3, at ¶¶ 84–95; see also 
Office of Biotechnology Activities, Report of the Secretary’s 
Advisory Committee on Genetics, Health, and Society, Gene 
Patents and Licensing Practices and Their Impact on Patient Access 
to Genetic Tests 39-45 (Dep’t of Health & Human Services, Apr. 
2010) [hereinafter SACGHS], available at http://oba.od.nih.
gov/oba/SACGHS/reports/SACGHS_patents_report_2010.pdf 
(collecting case studies examining limitations on clinical and patient 
access imposed by gene patents).
124.  SACGHS, supra note 124, at 38.
125.  Id. at 3.
126.  Id.
127.  Id. at 38.
128.  Id. at 39.
129.  Opposition, supra note 102, at 147.
of a sole provider or not, that insurance companies do 
not cover.130  In addition, the financial gain to service 
providers resulting from increased market size drives 
active negotiation with payers in order to increase patient 
pools, which in turn increases access, as evidenced by 
Myriad’s reduction of the number of self-pay patients to 
a single-digit percentage of its client base.131  
2.  Gene Patents Result in Decreased Quality 
of Genetic Testing
 It has been asserted that gene patents result in 
decreased quality of genetic testing in two ways.  First, 
the quality of the actual diagnostic test may remain 
stagnant, as market exclusivity fails to push service 
providers to improve testing.  For example, one French 
study found that Myriad’s BRCA testing procedure failed 
to detect ten to twenty percent of mutations.132  Some 
commentators suggest that increased competition results 
in improved testing regardless of whether available tests 
are of high quality and subject to excellent quality control 
procedures.133  On the other hand, there are several 
technical advantages to centralizing genetic testing, 
including the consistency that results from running 
all tests on the same equipment using standardized 
protocols and reagents and the ease of maintaining 
regulatory oversight.134  
 Second, in the sole provider context, 
confirmatory testing from an independent laboratory 
remains unavailable.135  Therefore, it is difficult to 
assess whether concerns about testing quality are well-
founded.136  Further, patients who receive inconclusive 
test results lack additional options for determining their 
predisposition to the development of disease.  However, 
Myriad has never received a single request from a 
patient or healthcare provider to conduct a second 
test at another lab.137  At least in the case of Myriad, 
130.  See generally SACGHS, supra note 124 (discussing 
insurance carriers’ refusal to cover genetic testing for long-QT 
syndrome, hearing loss, and spinocerebellar ataxia).
131.  R. Cook-Deegan et al., Impact of patents and licensing 
practices on access to genetic testing for inherited susceptibility to cancer: 
comparing breast and ovarian cancers to colon cancers, 12 Genetics 
in Medicine S30 (2010) (noting that Myriad’s testing is presently 
covered by over 300 providers).
132.  Steve Benowitz, French Challenge to BRCA1 Patent 
Underlies European Discontent, 94 J. Nat’l. Cancer. Inst. 80 
(2002).
133.  SACGHS, supra note 124, at 47.
134.  Id. at 47-48.
135.  Id. at 3.
136.  Id. at 46.
137.  Defendants’ Memorandum of Law (1) in Support 
of Their Motion for Summary Judgment and (2) in Opposition 
to Plaintiffs’ Motion for Summary Judgment, Association for 
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such quality concerns, in addition to recent scientific 
developments, led the company to develop a second, 
more robust test (the BART test), which is offered at no 
cost when indicated.138
3. Gene Patents Create Barriers to Research
 A common argument against the patenting of 
isolated human DNA molecules is that such patents 
impede research.  In the instant case, the plaintiffs 
allege that several scientists, due to potential liability for 
their research activities, discontinued their research on 
BRCA genes after Myriad secured its patents.139  Though 
Myriad is not currently targeting non-commercial 
researchers with its enforcement activities,140 there is no 
exemption for these researchers, meaning that it would 
be possible for Myriad to seek an injunction or institute 
a patent infringement action against these researchers. 
However, there is little evidence that gene patents held 
by Myriad or any other entity have a negative impact 
on basic or clinical research.  For example, an empirical 
study conducted at the University of Illinois examining 
125 academic researchers demonstrated little to no 
negative impact on research productivity.141  Another 
study by the German government found that DNA 
patents created no barrier to entry into fields of research 
where isolated DNAs had been patented.142  Though 
the prospect of receiving a patent is “not the major force 
motivating scientists,” that is not a justifiable reason to 
preclude genes as patentable subject matter, as patents 
are important for commercialization of genetic tests.143 
 There is one valid argument that pervades the 
issue of gene patents as an impediment to research—
there are possible negative effects on the future of 
genetic testing due to its dependence on the growing 
capacity to analyze multiple genes simultaneously.144 
Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 
Civ. 4515, 2009 WL 5785008, at 49 (S.D.N.Y. Dec. 23, 2009) 
[hereinafter Myriad’s Memo]. 
138.  Myriad Introduces Enhanced BRACAnalysis Test for 
Exceptionally High-Risk Cancer Patients (Aug. 1, 2006), http://
investor.myriad.com/releasedetail.cfm?ReleaseID=325803. An 
example of such an indication would be inconclusive BRCA1 test 
results.
139.  Plaintiffs’ Rule 56.1 Statement of Material Facts at 3-5, 
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 
09 Civ. 4515 (S.D.N.Y. Aug. 26, 2009) [hereinafter Plaintiff’s 
Statement].
140.  Association for Molecular Pathology v. U.S. Patent & 
Trademark Office, 669 F. Supp. 2d. 365, 379 (S.D.N.Y. Nov. 2, 
2009).
141.  Myriad’s Memo, supra note 136, at 45.
142.  Id.
143.  SACGHS, supra note 124, at 1-2.
144.  Id. at 3.
Because approximately twenty percent of genes have 
been patented, development of multiplex tests and 
parallel sequencing will be dependent on acquisition 
of rights to multiple gene patents.145  Similarly, whole-
genome sequencing would require acquisition of 
rights to most, if not all, existing gene patents.146  The 
cumulative costs of multiple licenses, the associated 
costs of negotiations, and the right of a patent holder 
to refuse to license his invention could prevent such 
products from ever reaching the market.147
B.  The Arguments for Gene Patenting
1.   Purified and Isolated DNA Is Patentable 
Subject Matter
 From the beginning, the district court 
appeared to view Myriad’s assertion of the isolation and 
purification of DNA as transforming it into something 
distinctly different in character with hostility, framing 
such practice as a ‘“lawyer’s trick’ that circumvents the 
prohibitions on the direct patenting of the DNA in 
our bodies.”148  However, the district court’s assertion 
that DNA’s unique characteristics differentiate it 
from other chemical compounds149 seems to rely on 
philosophical underpinnings in lieu of the scientific 
analysis that provides the basis for this so-called 
“lawyer’s trick.”  Such philosophical justifications are 
evident in the court’s statement that “DNA represents 
the physical embodiment of biologic information” and 
“DNA’s existence in isolated form alters neither this 
fundamental quality of DNA as it exists in neither the 
body nor the information it encodes.”150
 The difference in the structural and functional 
properties of isolated DNA when compared to those 
of native DNA is critically important to the utility and 
function of such claimed isolated DNA molecules.151 
Native DNA is protected in the cell because it remains 
surrounded by proteins and stably embedded in 
chromosomes.152  Removal of associated cellular products 
that facilitate packaging of the DNA into a chromosome 
by isolation and purification fundamentally alters the 
chemical structure of DNA.  Such isolation renders 
DNA molecules useful as physical probes and primers 




148.  Ass’n for Molecular Pathology, 702 F. Supp. 2d. at 185.
149.  Id. at 228.
150.  Id. at 185.
151.  Myriad’s Memo, supra note 136, at 31.
152.  Id at 30.
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allowing diagnosis of increased cancer susceptibility.153 
Thus, the utility of such molecules is based on their ability 
to target and interact with other DNA molecules, not 
just the biological information contained within.  Such 
a function is dependent on an isolated DNA molecule’s 
unique structure and chemistry,154 a structure and 
chemistry that, importantly, is lacking in native DNA 
molecules.  As the court acknowledged, purified DNA 
can be used as a tool for biotechnological applications 
for which native DNA cannot be used.155  
 The uncontradicted scientific evidence 
demonstrates that the isolation and purification of a 
DNA molecule results in a new and useful composition 
of matter in satisfaction of the requirements of 35 U.S.C. 
§ 101 or an invention in the field of biotechnology in 
satisfaction of Art. 52 of the EPC.156  This composition 
of matter is not a law of nature, physical phenomenon, or 
abstract idea, and so it does not fall within the exceptions 
to § 101 established by case law.157  Similarly, it does not 
fall within the EPC exceptions of a discovery, scientific 
theory, or mathematical method.158  In determining 
patent eligibility, isolated DNA molecules should be 
treated no differently from other chemical compounds, 
and the courts’ misplaced focus on the information-
containing or information-delivering qualities of DNA 
should not be used to justify such differential treatment.
2.  Gene Patents Stimulate Investment
 Though individual scientists may not be 
motivated by the prospect of receiving a patent, 
“meaningful gene-disease associations are confirmed 
only if the initial discoveries are followed by large scale 
replication and validation studies using multiple sample 
sets, the costs of which are prohibitive for many research 
groups.”159  Congress’s enactment of the Bayh-Dole 
Act, which established a uniform policy among federal 
agencies that academic institutions may patent inventions 
arising from federally supported research and license 
them to companies, is a direct acknowledgment of this 
153.  Id. at 32; See, e.g., U.S. Patent No. 5,693,473 (filed June 
7, 1995).
154.  Id. at 33.
155.  702 F. Supp.2d at 196.
156.  35 U.S.C. § 101; European Patent Convention, supra 
note 86, at art. 52(1).
157.  Diamond v. Chakrabarty, 447 U.S. at 309 (setting forth 
the exceptions of laws of nature, physical phenomena, and abstract 
ideas).
158.  European Patent Convention, supra note 86, at art. 
52(2).
159.  SACGHS, supra note 123, at 23.
economic reality.160  It was premised on the belief that 
absent exclusive patent rights from licenses, companies 
will not invest resources to develop an invention into 
a product because free-riders could copy the finished 
product.161  Indeed, the strength of a company’s 
intellectual property strategy and position is one of the 
top three questions posed by investors.162  Thus, due 
to the enormous sums of money required to discover, 
develop, test, and approve genetic tests, notwithstanding 
the time it takes to develop such tests, protection of the 
related intellectual property is critical.163  
 Had it not been for the exclusive patent rights 
it obtained regarding BRCA1/2 and the infusion of 
capital that follows from such exclusivity, Myriad would 
never have been created, and its BRCA1/2 tests would 
never have been brought to the market, resulting in a 
true barrier to patient access.164  For example, Eli Lilly 
agreed to fund Myriad’s ongoing research efforts in 
return for licensing privileges on diagnostic kits and 
therapeutic products related to BRCA1.165  Similarly, 
the prospect of gene patents has also been critical 
to funding the development of genetic testing for 
other diseases, including hereditary hemochromatosis 
(Mercator Genetics), spinal diseases (Axial Biotech), 
diseases that predominantly affect women (Juneau 
Biosciences), spinal muscular atrophy (Claire Altman 
Heine Foundation), and muscular dystrophy (Boston 
Children’s Hospital).166  Though the federal government 
remains the major funder of basic genetic research,167 
private investment is necessary to translate basic research 
from the lab bench to the patient’s bedside.
3.  Gene Patents Stimulate Research
 While it is evident that gene patents stimulate 
the translational research needed to drive genetic testing 
innovation from the lab to market, it is also clear that 
gene patents stimulate basic research and discovery.  Since 
Myriad’s public disclosure of the BRCA1 gene in 1994 
and BRCA2 gene in 1996, more than 18,000 scientists 
160.  Id. at 28.
161.  Id. at 29.
162.    Lisa A. Haile, IP Position Critical to Biotech Investment, 
30(7) Wall Street BioBeat (April 1, 2010), http://www.
genengnews.com/gen-articles/ip-position-critical-to-biotech-
investment/3235/ One investment banker stated that “[w]e know 
that if the IP position is not strong, it is unlikely that we will pursue 
the opportunity further.” SACGHS, supra note 124, at 29.
163.  Haile, supra note 16; SACGHS, supra note 124, at 29.
164.  Myriad’s Memo, supra note 136, at 47. 
165.  SACGHS, supra note 124, at 23.
166.  Id. at 24-26.
167.  Id. at 25.
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have researched the genes, leading to the publication of 
over 5,600 papers on BRCA1 and over 3,000 papers on 
BRCA2.168  Interestingly, the individual plaintiffs and 
their declarants in the instant case published forty-eight 
peer-reviewed research papers on the BRCA1/2 genes 
without any interference from Myriad.169  Apparently, 
Myriad’s gene patents did nothing to impede their 
research.  Furthermore, Myriad has found it in its 
own best interest to freely allow academic scientists to 
conduct research studies on the BRCA1/2 genes, provide 
direct assistance to such researchers, and publish and 
actively disseminate its own research into the public 
domain.170  Such stimulation of research is not unique 
to the field of breast cancer.  Human Genome Sciences 
provided collaborators at Johns Hopkins University 
access to the company’s proprietary database of DNA 
sequences coding for receptor proteins, resulting in 
the discovery of the MLH1 gene involved in colon 
cancer.171  Though opponents of gene patenting may see 
the biotech industry as capitalistic and self-serving, such 
characteristics have resulted in an increased recognition 
by biotech entities of the mutual benefits that flow from 
collaborations with independent groups engaged in 
basic research. 
IV. Conclusion
 The United States Court of Appeals for the 
Federal Circuit should overturn the district court’s 
decision in Myriad.  First and foremost, isolated DNA 
molecules fit within the definition of patentable subject 
matter as defined by statute and developed through case 
law.  In addition, though there are valid arguments against 
the patenting of such molecules, including the creation 
of barriers to patient access, research, and improvement 
of test quality, when weighed against arguments in 
support this type of patenting, namely stimulation of 
research and investment, it becomes clear that patenting 
of isolated DNA molecules will have the most benefit to 
the public as a whole.  The intellectual property position 
of biotech companies is one of the most important 
factors potential investors consider, and, without 
significant capital investment, research groups would 
lack the considerable resources required to translate 
these technologies into reliable, effective diagnostic 
tests and treatments.  The future of genetic medicine 
looks promising, offering a number of innovations for 
168.  Myriad’s Memo, supra note 136, at 46.
169.  Id.
170.  Id at 47.
171.  SACGHS, supra note 124, at 25; R. Cook-Deegan et al., 
supra note 130 at S29. 
identifying and curing heritable disorders—a future that 
will never happen without patent protection.
